Live Updates > Live Update Details
2025-07-30 17:21:52
[Sihuan Pharmaceutical's innovative drug Aneprazole Sodium Enteric-coated Tablets has completed the first enrollment in the Phase III clinical trial] ⑴Sihuan Pharmaceutical announced that its subsidiary Xuanzhu Biotechnology's independently developed Class 1 innovative drug Aneprazole Sodium Enteric-coated Tablets for the treatment of reflux esophagitis has completed the first subject enrollment. The study will evaluate the drug's efficacy and long-term safety, providing key data support for the marketing application. ⑵Aneprazole Sodium Enteric-coated Tablets is the first completely independently developed PPI innovative drug in China, and it is also the only PPI innovative drug currently. Data shows that in 2024, there were approximately 38.3 million patients with reflux esophagitis in China, and it is expected to reach 42.4 million in 2032.
